Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.
Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R, Kaneko T, Takahashi A, Sugimura K, Koike Y, Ishii J, Sakamoto N; SNK-860 Diabetic Neuropathy Study Group.
Diabetes Care. 2001 Oct;24(10):1776-82. Erratum in: Diabetes Care 2002 Feb;25(2):413-4. PMID: 11574441 [PubMed - indexed for MEDLINE]Related articlesFree article